Eprex
Sponsors
Azidus Brasil, Dong-A ST Co., Ltd., UBI Pharma Inc., Groupe Francophone des Myelodysplasies, Association Athletes For Transparency
Conditions
AnemiaAnemia of Chronic Kidney DiseaseChronic Kidney DiseaseHealthyMDSMyelodysplastic SyndromesRenal AnemiaRenal Insufficiency, Chronic
Phase 1
To Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers
NCT02580006
Start: 2015-11-30End: 2016-03-31Target: 42Updated: 2015-10-20
Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents
NCT03276910
Start: 2017-09-08End: 2018-06-01Target: 24Updated: 2017-09-08
Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.
CompletedNCT03572647
Start: 2012-11-30End: 2013-05-31Updated: 2022-11-03
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
RecruitingNCT05181735
Start: 2022-05-18End: 2029-06-19Target: 150Updated: 2026-03-05
Phase 3
Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.
TerminatedNCT01695759
Start: 2013-12-31End: 2018-01-31Updated: 2018-08-20
Study to Compare the Safety and Efficacy of UB-851 and Eprex®
CompletedNCT02708914
Start: 2016-03-31End: 2021-10-31Updated: 2023-12-06
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
Active, not recruitingNCT03223961
Start: 2018-03-26End: 2028-10-01Target: 124Updated: 2026-09-11
To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)
NCT03521713
Start: 2016-03-01End: 2021-03-31Target: 214Updated: 2019-12-10